secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0001193125-24-216320
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa ORX750 Phase 1 restores normative wakefulness at 2.5 mg, no hepatotoxicity; Phase 2 in Q4
--------------------------------------------------------------------------------

- 2.5 mg dose achieved mean sleep latency of 32 min on MWT vs placebo 17 min (p=0.01), restoring normative wakefulness.
- No hepatotoxicity, visual disturbances, or common OX2R agonist AEs observed; all AEs mild/transient.
- 1.0 mg also statistically significant: mean sleep latency 18 min vs placebo 10 min (p=0.04).
- Plans to initiate Phase 2 studies in narcolepsy NT1, NT2, and idiopathic hypersomnia in Q4 2024.
- Linear PK supports once-daily dosing; systemic exposure dose-proportional.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312524216320/0001193125-24-216320-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312524216320/d857057d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-216320

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer